(Updates to add Hong Kong ticker)
Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Shandong Shengdi received regulatory acceptance in China for the marketing application of its HRS-7535 tablets.
The drug is indicated for blood sugar control in patients with type two diabetes mellitus, according to a Wednesday aftermarket filing with the Shanghai bourse.
Shares of the company were up 1% in recent trade.